Senti Biosciences Holdings (SNTI) Research & Development (2021 - 2025)
Senti Biosciences Holdings (SNTI) posted quarterly Research & Development of $7.8 million for Q4 2025, little changed year-over-year from $7.8 million in Q4 2024, and down 26.21% quarter-over-quarter from $10.5 million in Q3 2025.
Senti Biosciences Holdings (SNTI) Research & Development (2021 - 2025) Analysis & Trends
Senti Biosciences Holdings' Research & Development history runs 5 years deep, the most recent figure standing at $7.8 million for Q4 2025.
- In Q4 2025, Research & Development changed 0.15% year-over-year to $7.8 million; the TTM figure through Dec 2025 stood at $37.6 million (up 9.4% YoY), while the FY2025 annual figure was $37.6 million, up 9.4% from the prior year.
- Research & Development for Q4 2025 stood at $7.8 million, down from $10.5 million in the prior quarter.
- The five-year high for Research & Development was $10.5 million in Q3 2025, with the low at $5.2 million in Q2 2021.
- The 5-year median for Research & Development is $7.8 million (2024), against an average of $8.0 million.
- The sharpest annual moves came in 2022 and 2023: Research & Development surged 76.64% in 2022, then declined 25.64% in 2023.
- Senti Biosciences Holdings' Research & Development stood at $6.4 million in 2021, then rose by 9.8% to $7.0 million in 2022, then increased by 29.63% to $9.1 million in 2023, then decreased by 14.8% to $7.8 million in 2024, then retreated by 0.15% to $7.8 million in 2025.
- Business Quant data shows SNTI's Research & Development at $7.8 million in Q4 2025, $10.5 million in Q3 2025, and $10.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 97.90 Mn |
| 10 | Senti Biosciences Holdings | 12.06 Mn | 12.06 Mn | - | 7.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.76 Mn |
| Sep 30, 2025 | 10.52 Mn |
| Jun 30, 2025 | 10.03 Mn |
| Mar 31, 2025 | 9.28 Mn |
| Dec 31, 2024 | 7.77 Mn |
| Sep 30, 2024 | 8.66 Mn |
| Jun 30, 2024 | 9.15 Mn |
| Mar 31, 2024 | 8.78 Mn |
| Dec 31, 2023 | 9.12 Mn |
| Sep 30, 2023 | 9.09 Mn |
| Jun 30, 2023 | 6.88 Mn |
| Mar 31, 2023 | 7.06 Mn |
| Dec 31, 2022 | 7.04 Mn |
| Sep 30, 2022 | 6.52 Mn |
| Jun 30, 2022 | 9.25 Mn |
| Mar 31, 2022 | 7.60 Mn |
| Dec 31, 2021 | 6.41 Mn |
| Sep 30, 2021 | 5.41 Mn |
| Jun 30, 2021 | 5.24 Mn |